Entera Bio (ENTX) announced that its Board of Directors has appointed Geno Germano as Chairman of the Board, effective February 4, 2026. Mr. Germano succeeds Gerald Lieberman, who is stepping down as Chairman. Germano is a pharmaceutical and life sciences executive with more than three decades of leadership experience spanning development, commercialization, and global operations. He held senior leadership roles at Pfizer (PFE), including as Group President of Pfizer’s Global Innovative Pharmaceutical Business.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENTX:
- Entera Bio Expands OPKO Partnership, Adds New Director
- Opko Health Entera Bio, Entera Bio expand partnership to advance PTH tablet
- Entera Bio announces expected milestones for Q1 in 2026
- Entera Bio ‘congratulates’ FNIH-ASBMR-SABRE team on FDA endpoint qualification
- Entera Bio announces new data on long-acting PTH tablet